166 related articles for article (PubMed ID: 32827494)
21. Development of a Physiologically Relevant Population Pharmacokinetic in Vitro-in Vivo Correlation Approach for Designing Extended-Release Oral Dosage Formulation.
Kim TH; Shin S; Bulitta JB; Youn YS; Yoo SD; Shin BS
Mol Pharm; 2017 Jan; 14(1):53-65. PubMed ID: 27809538
[TBL] [Abstract][Full Text] [Related]
22. Phospholipid-based solid drug formulations for oral bioavailability enhancement: A meta-analysis.
Fong SY; Brandl M; Bauer-Brandl A
Eur J Pharm Sci; 2015 Dec; 80():89-110. PubMed ID: 26296863
[TBL] [Abstract][Full Text] [Related]
23. Effect of lipids on absorption of carvedilol in dogs: Is coadministration of lipids as efficient as a lipid-based formulation?
Alskär LC; Parrow A; Keemink J; Johansson P; Abrahamsson B; Bergström CAS
J Control Release; 2019 Jun; 304():90-100. PubMed ID: 31047962
[TBL] [Abstract][Full Text] [Related]
24. Enhanced bioavailability and hepatoprotectivity of optimized ursolic acid-phospholipid complex.
Biswas S; Mukherjee PK; Harwansh RK; Bannerjee S; Bhattacharjee P
Drug Dev Ind Pharm; 2019 Jun; 45(6):946-958. PubMed ID: 30767678
[TBL] [Abstract][Full Text] [Related]
25. Biopharmaceutical classification of poorly soluble drugs with respect to "enabling formulations".
Buckley ST; Frank KJ; Fricker G; Brandl M
Eur J Pharm Sci; 2013 Sep; 50(1):8-16. PubMed ID: 23583787
[TBL] [Abstract][Full Text] [Related]
26. In-vitro permeability screening of melt extrudate formulations containing poorly water-soluble drug compounds using the phospholipid vesicle-based barrier.
Kanzer J; Tho I; Flaten GE; Mägerlein M; Hölig P; Fricker G; Brandl M
J Pharm Pharmacol; 2010 Nov; 62(11):1591-8. PubMed ID: 21039543
[TBL] [Abstract][Full Text] [Related]
27. A win-win solution in oral delivery of lipophilic drugs: supersaturation via amorphous solid dispersions increases apparent solubility without sacrifice of intestinal membrane permeability.
Miller JM; Beig A; Carr RA; Spence JK; Dahan A
Mol Pharm; 2012 Jul; 9(7):2009-16. PubMed ID: 22632106
[TBL] [Abstract][Full Text] [Related]
28. Improvement of Oral Absorption of Poorly Water-Soluble Drugs by Solid Dispersions with Amphiphilic Phospholipid Polymer.
Yoshie K; Ishihara K
J Pharm Sci; 2022 Nov; 111(11):3141-3148. PubMed ID: 36028136
[TBL] [Abstract][Full Text] [Related]
29. Influence of polymer molecular weight on in vitro dissolution behavior and in vivo performance of celecoxib:PVP amorphous solid dispersions.
Knopp MM; Nguyen JH; Becker C; Francke NM; Jørgensen EB; Holm P; Holm R; Mu H; Rades T; Langguth P
Eur J Pharm Biopharm; 2016 Apr; 101():145-51. PubMed ID: 26899127
[TBL] [Abstract][Full Text] [Related]
30. Combined use of crystalline salt forms and precipitation inhibitors to improve oral absorption of celecoxib from solid oral formulations.
Guzmán HR; Tawa M; Zhang Z; Ratanabanangkoon P; Shaw P; Gardner CR; Chen H; Moreau JP; Almarsson O; Remenar JF
J Pharm Sci; 2007 Oct; 96(10):2686-702. PubMed ID: 17518357
[TBL] [Abstract][Full Text] [Related]
31. Mechanistic insights into effect of surfactants on oral bioavailability of amorphous solid dispersions.
Schittny A; Philipp-Bauer S; Detampel P; Huwyler J; Puchkov M
J Control Release; 2020 Apr; 320():214-225. PubMed ID: 31978445
[TBL] [Abstract][Full Text] [Related]
32. Comparative evaluation of proliposomes and self micro-emulsifying drug delivery system for improved oral bioavailability of nisoldipine.
Nekkanti V; Rueda J; Wang Z; Betageri GV
Int J Pharm; 2016 May; 505(1-2):79-88. PubMed ID: 27041124
[TBL] [Abstract][Full Text] [Related]
33. Simultaneous assessment of in vitro lipolysis and permeation in the mucus-PVPA model to predict oral absorption of a poorly water soluble drug in SNEDDSs.
Falavigna M; Brurok S; Klitgaard M; Flaten GE
Int J Pharm; 2021 Mar; 596():120258. PubMed ID: 33486034
[TBL] [Abstract][Full Text] [Related]
34. Formulation and Pharmacokinetic Evaluation of Polymeric Dispersions Containing Valsartan.
Chella N; Daravath B; Kumar D; Tadikonda RR
Eur J Drug Metab Pharmacokinet; 2016 Oct; 41(5):517-26. PubMed ID: 26156887
[TBL] [Abstract][Full Text] [Related]
35. Biomimetic Dissolution: A Tool to Predict Amorphous Solid Dispersion Performance.
Puppolo MM; Hughey JR; Dillon T; Storey D; Jansen-Varnum S
AAPS PharmSciTech; 2017 Nov; 18(8):2841-2853. PubMed ID: 28560506
[TBL] [Abstract][Full Text] [Related]
36. Effect of polymer type and drug dose on the in vitro and in vivo behavior of amorphous solid dispersions.
Knopp MM; Chourak N; Khan F; Wendelboe J; Langguth P; Rades T; Holm R
Eur J Pharm Biopharm; 2016 Aug; 105():106-14. PubMed ID: 27212472
[TBL] [Abstract][Full Text] [Related]
37. Amorphous multi-system of celecoxib improves its anti-inflammatory activity in vitro and oral absorption in rats.
Choi JS; Ahn JB; Park JS
Int J Pharm; 2019 Jan; 555():135-145. PubMed ID: 30458259
[TBL] [Abstract][Full Text] [Related]
38. Proliposomes of exemestane for improved oral delivery: formulation and in vitro evaluation using PAMPA, Caco-2 and rat intestine.
Hiremath PS; Soppimath KS; Betageri GV
Int J Pharm; 2009 Oct; 380(1-2):96-104. PubMed ID: 19616608
[TBL] [Abstract][Full Text] [Related]
39. Preparation, characterization and in vitro/vivo evaluation of tectorigenin solid dispersion with improved dissolution and bioavailability.
Shuai S; Yue S; Huang Q; Wang W; Yang J; Lan K; Ye L
Eur J Drug Metab Pharmacokinet; 2016 Aug; 41(4):413-22. PubMed ID: 25669445
[TBL] [Abstract][Full Text] [Related]
40. In silico predictions of gastrointestinal drug absorption in pharmaceutical product development: application of the mechanistic absorption model GI-Sim.
Sjögren E; Westergren J; Grant I; Hanisch G; Lindfors L; Lennernäs H; Abrahamsson B; Tannergren C
Eur J Pharm Sci; 2013 Jul; 49(4):679-98. PubMed ID: 23727464
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
